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Abstract
Since 2013 in Emilia-Romagna, Italy, surveillance information generated in the public health
and in the animal health sectors has been shared and used to guide public health interven-
tions to mitigate the risk of West Nile virus (WNV) transmission via blood transfusion. The
objective of the current study was to identify and estimate the costs and benefits associated
with this One Health surveillance approach, and to compare it to an approach that does not
integrate animal health information in blood donations safety policy (uni-sectoral scenario).
Costs of human, animal, and entomological surveillance, sharing of information, and trig-
gered interventions were estimated. Benefits were quantified as the averted costs of poten-
tial human cases of WNV neuroinvasive disease associated to infected blood transfusion. In
the 2009–2015 period, the One Health approach was estimated to represent a cost saving
of €160,921 compared to the uni-sectoral scenario. Blood donation screening was the main
cost for both scenarios. The One Health approach further allowed savings of €1.21 million in
terms of avoided tests on blood units. Benefits of the One Health approach due to short-
term costs of hospitalization and compensation for transfusion-associated disease poten-
tially avoided, were estimated to range from €0 to €2.98 million according to the probability
of developing WNV neuroinvasive disease after receiving an infected blood transfusion.
Introduction
In Emilia-Romagna region, Italy, West Nile virus (WNV) was detected for the first time in six
horses with neurological symptoms in September 2008 in the vicinity of Ferrara province [1].
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At the same time and in the same area, the first Italian human case of WNV neuroinvasive dis-
ease (WNND) was confirmed [2]. In total, three cases of WNND were confirmed in the region
in 2008. Since 2009, an integrated and multi-disciplinary WNV surveillance system targeting
humans, wild birds, horses, and mosquitoes has been implemented and adapted over time.
The main objectives of this surveillance system are: (1) the early detection of WNV circulation
in the environment; and (2) the mitigation of viral transmission risk via blood and solid organ
donations [3].
From 2009 to 2012, the blood donations safety policy was based on a uni-sectoral approach.
All blood donations in a given province were tested for WNV immediately after the first detec-
tion of a WNND case in that province until November 30, and also from July 1 to November
30 in the following year.
Since 2013, in agreement with the national blood authority, Emilia-Romagna has tentatively
adopted a One Health approach to surveillance information use in blood donations safety pol-
icy [4–6]. Timely data on WNV detection generated by animal surveillance are integrated to
trigger public health interventions on blood donors. Confirmation of WNV in any species tar-
geted by the surveillance system in a given province activates the systematic individual Nucleic
Acid Amplification (NAT) testing of blood donations in that province until the end of the
annual transmission season (30 November), as requested by European regulation [7]. No addi-
tional testing is carried out during the following transmission season unless the surveillance
system signals viral circulation again. This One Health approach is based on the cross-sectoral
collaboration of different public institutions, resulting in a network linking human, animal,
and environmental health, under the coordination of the regional working group on vector-
borne diseases.
The implementation of surveillance systems and control measures for infectious diseases
can be resource intensive activities. From an economic standpoint, the rational allocation of
resources to those activities is based on the principle that associated overall costs are out-
weighed by benefits in terms of reduction of costs of diseases [8]. Economic assessment tools
allow estimating the efficiency in terms of resource use of these approaches and guide policy
and decision making of disease mitigation. The majority of this work focuses on uni-sectoral
approaches to disease control and little has been carried out to establish the comparative effi-
ciency in economic terms of One Health approaches to disease mitigation [8]. Yet, such infor-
mation is key in the development of cost-effective zoonoses control, including for WNV.
The objective of the current study was to identify and estimate costs and benefits associated
with the One Health approach used to guide blood donation safety policy for WNV in Emilia-
Romagna in the 2009–2015 period.
Materials and methods
To guide the analysis a framework developed by Babo Martins et al. [9] was applied. The
framework proposes the conceptualization of the links between surveillance activities across
the two sectors and public health and animal health triggered interventions. Through such
conceptualization, it was then possible to identify costs and benefit streams associated with
surveillance activities (Fig 1). The next steps entail the valuation of the cross-sectoral costs and
benefits identified. In this analysis, costs and benefits of surveillance designs and triggered
interventions were estimated considering two scenarios. The One Health scenario currently
implemented in Emilia-Romagna since 2013 as described in the introduction, and a uni-sec-
toral scenario, corresponding to the national regulation on blood safety. The latter triggers the
activation of mandatory WNV testing with the confirmation of a human WNND or West Nile
fever (WNF) case in a given province [10], and systematic testing is carried out in that
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province until the end of the vector season (30 November) and also between 1 July and 30
November in the following transmission season [11].
Cost components and data sources
The Emilia-Romagna integrated WNV surveillance system includes human, entomological,
ornithological, and horse surveillance, and triggered public health interventions (i.e. blood
screening, vector control, and communication campaigns). Detailed description of this sur-
veillance system has been previously provided by Angelini et al. [12] and Calzolari et al. [13].
Bellini et al. [3] performed a first cost evaluation of the regional integrated surveillance system
for the 2009–2013 period. In this study, the same methodology was applied to update the costs
of entomological and ornithological surveillance, and blood screening activity for 2014 and
2015, using the A and B scenarios identified in that work as the uni-sectoral and One Health
scenarios, respectively. In addition to this, costs of human and horse surveillance, sharing of
information, vector control interventions, and communication campaigns were estimated for
the study period. For the One Health scenario, costs of human, entomological, ornithological,
horse surveillance, and sharing of information were also considered. For the uni-sectoral sce-
nario only the costs of human surveillance were included. For both scenarios, costs of the trig-
gered public health interventions were estimated. The details for the estimation of these cost
Fig 1. Identification of the links between West Nile virus (WNV) surveillance activities in the animal
and human population, the wider public health disease mitigation system, and the benefit
components associated, following the conceptual framework used in this analysis [9]. Dotted lines:
elements identified but not considered in the economic evaluation. WNV integrated surveillance system in
Emilia-Romagna, 2009–2015.
https://doi.org/10.1371/journal.pone.0188156.g001
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components are detailed below. Table 1 provides summarized information on all cost items
considered in the analysis.
The cost of human surveillance was estimated for the study period considering the mean
cost of diagnosis of WNND on a suspect case, times the number of suspect cases. Costs
included value added tax (VAT), labour cost was not included [3]. The cost of horse surveil-
lance was determined as the cost of diagnosis (screening and confirmation) of WNV in the
study period, times the number of suspect cases. Costs included personnel and VAT, and were
extracted from the invoice value of the official laboratory for WNV diagnosis in animals and
vectors (IZSLER) price list [14].
Sharing of information to guide public health interventions to mitigate the risk of viral
transmission via blood transfusion occur through regular meetings of the regional working
group on vector-borne diseases, an epidemiologic bulletin periodically elaborated during the
vector season, telephone, and email. The cost of information sharing was estimated consider-
ing the number and duration of the meetings, the number of participants, and the hourly wage
of public health workers (i.e. official veterinarians). Costs associated with time used in commu-
nication and information sharing through bulletins, emails and phone calls could not be
estimated.
Costs of communications campaigns were estimated as the yearly funding for public infor-
mation activities provided through the regional deliberation on VBD throughout the study
period [15, 16]. This funding was designated for the production and dissemination of informa-
tive brochures, and for the design, update, and maintenance of informative websites.
The difference was calculated between the mean expenditure allocated to ground adult
mosquito control interventions after the notification of communicable diseases in Emilia-
Romagna in a two-year period with no human WNND cases (2010–2011), and the same item
of expenditure in a year characterized by the notification of human WNND cases (2009). It
was assumed this difference could be attributable to vector control interventions triggered by
the occurrence of human WNND cases. This expenditure was considered as the mean annual
cost for vector control in those years characterized by the occurrence of WNND human cases.
Data were obtained from the Emilia-Romagna report on the costs allocated in each local health
unit (LHU) for vector control interventions within the regional arboviruses surveillance plan
in the 2008–2011 period [17].
Benefits considered and data sources
In the One Health scenario, surveillance data generated in the animal and vector population
provided an early warning signal of WNV presence in these populations. In 2013 and 2014,
this early warning enabled the detection of six infected blood donations in three provinces,
before the onset of the first human cases of WNND or WNF in the same provinces. These
infected blood donations would not have been tested for WNV following the national guide-
lines on blood safety (uni-sectoral scenario). Thus, marginal benefits of the One Health sce-
nario were estimated as the averted costs of potential WNND cases associated to the
transfusion of infected blood components intercepted in the One Health scenario only. Con-
sidering that most donations are whole blood units and each of these is systematically frac-
tioned into three different blood components (red cells, buffy coat/platelets, and plasma), a
number of 18 potential blood recipients could receive an infected transfusion. To the best of
our knowledge, there is a lack of literature on the probability of developing neurologic disease
after receiving a WNV infected transfusion. Thus, minimum, intermediate, and maximum val-
ues of 0.66%, 10%, and 100%, respectively, were assumed to consider three effect sizes or sce-
narios. In the best-case scenario, the probability of developing neurologic disease after infected
Cost and benefits integrated WNV surveillance
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Table 1. Cost items included for the estimation of costs of the West Nile virus (WNV) integrated surveillance system in Emilia-Romagna, 2019–
2015.
Item Description Value Unit Details Source
Surveillance activities
Human
surveillancea
Mean cost of diagnosis of WNND on suspect
cases:
PCR, IFA, microneutralisation on blood and
cerebrospinal fluid
74 Euro/case Personnel not included,
value added tax (VAT)
included
[3]
Horse
surveillanceb
Mean cost of diagnosis of WNV neurologic
disease on suspect horses:
Screening: IgM ELISA on serum and PCR on
EDTA-blood of alive suspect horses
20 Euro/case Personnel and VAT included [14]
Confirmation of each positive sample: PCR,
cell culture and sequencing
30 Euro/case
Ornithological
surveillance
Wild birds collection 50 Euro/
consignment
Lump sum per consignment [3]
Screening: PCR on pool of organs (brain
spleen heart and kidney) of individual wild birds
15 Euro/bird Personnel and VAT included [3] for 2009–2013;
[14] for 2014–2015
Confirmation of each positive pool: PCR, cell
culture and sequencing
30 Euro/ pos.
bird
Entomological
surveillance
Screening: PCR on each mosquito pool 15 Euro/pool
Confirmation of each positive pool: PCR, cell
culture and sequencing
30 Euro/ pos.
pool
Mosquito collection, species determination and
pools preparation
Variablec Euro/year Lump sum for each season [3] for 2009–2013;
[15,16] for 2014–2015
Sharing of
information
Mean number of meetings of the regional
working group on vector-borne diseases per
year
10 Number Marco Tamba, personal
communication March
2016
Mean number of participants per meeting 10 Number
Mean duration of each meeting 4 Hours
Hourly wage of official veterinarians 56 Euro /hour National Job Agreement
for Public Health Sector
wage
Triggered interventions
Blood testing Nucleic Acid Amplification Test (NAT) on each
blood-donor sample
Variabled Euro/test Personnel not included, VAT
included
[3]
Communication
campaigns
Production and dissemination of informative
brochures; design, update and maintenance of
a website
15,000 Euro/year Yearly funding for public
information activities
[15,16]
Vector control Average annual cost attributable to vector
control interventions (ground adult mosquito
control) triggered by the notification of human
WNND cases
102,870 Euro/year Average annual cost
attributable to vector control
interventions due to WNND
in 2009
[17]
WNND: West Nile virus neuroinvasive disease; VBD: vector-borne diseases
a The human surveillance system consists in case reporting and epidemiological investigation throughout the whole year overall regional territory, and in
active identification of WNND human cases. According to the national case definition, every patient presenting fever ( 38.5˚C) and a neurologic
manifestation (i.e. encephalitis, aseptic meningitis or acute polyradiculoneuritis Guillain–Barre syndrome, or acute flaccid paralysis) is considered as a
suspect, and is promptly reported to the Public Health Department to be tested for WNV [10].
b Continuous syndromic surveillance for WNV neurologic disease in the horse population is carried out year-round overall the regional territory. Every horse
presenting neurological signs (i.e. weakness, usually in the hind limbs, paralysis or partial paralysis, irregular gait, muscle twitching, proprioceptive deficits,
impaired vision, flaccid paralysis of the lower lip, paralysis or partial paralysis of facial and labial muscles, teeth grinding) is considered as a suspect, it is
mandatory reported to the veterinary authorities, and is tested for WNV [18].
c The annual sum allocated for mosquito collection, species determination and pools preparation was €75,000 in the 2014–2015 period, €60,000 in 2013,
and €50,000 for the 2009–2012 period.
d The cost for a single NAT-test on a blood-donors sample was €11.32 in the 2013–2015 period, €12.10 in 2012, and €12.00 in the 2009–2011 period.
https://doi.org/10.1371/journal.pone.0188156.t001
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transfusion was assumed to correspond to that after bites of infected mosquitoes (0.66%) [19].
An intermediate value of 10% was assumed considering that about 20% of infected persons
develop fever and other clinical symptoms including headache, tiredness, and body aches [19].
Finally, in the worst-case scenario, a 100% probability of transfusion transmitted WNND was
assumed considering that a high proportion of blood recipients are immunocompromised and
many of them are subject to chronic or intensive transfusion treatments [10]. Therefore, bene-
fits of the One Health scenario were calculated as the avoided short term cost of hospitalization
and avoided compensation for transfusion-associated disease (TAD) of 0, 2, and 18 potential
WNND cases, according to three effect sizes or scenarios for transfusion-associated disease
mentioned above, respectively. Due to hospital data anonymization, it was not possible to col-
lect further data on any additional costs related to WNND long term sequelae (e.g. home care,
rehabilitation, durable medical equipment, medication or medical appointment) incurred by
the WNND cases when discharged from the hospital. Our study only included hospitalization
costs of WNND cases for the estimation of benefits. Benefits were calculated as averted costs
related to avoided short term cost of hospitalization and avoided compensation for TAD of
potential human cases of WNND associated to infected blood component transfusions. Cost
items and hospital data considered for the estimation of benefits are reported in Tables 2 and
3, respectively. Additional data on WNND cases hospitalization is provided in S1 Table of sup-
plementary information. Data on WNND cases were acquired by the Emilia-Romagna Region
Table 2. Items included in the calculation of avoided short term cost of hospitalization and avoided compensation for transfusion-associated dis-
ease for the estimation of benefits, West Nile virus (WNV) integrated surveillance system in Emilia-Romagna, 2009–2015.
Item Description Value Unit Details Source
Mean short term cost of hospitalization of WNV neuroinvasive disease (WNND)
Hospitalization data Date of admission and discharge
to and from each hospital ward
Variable Date Hospital discharge form
(HDF) database
Hospital ward type Description NA Intensive therapy, neurology,
infectious and tropical diseases,
haematology, neurology-rehabilitation
etc.
Duration of hospitalization in
each hospital ward
Table 3 Days
Primary and secondary
diagnosis during hospitalization
Description NA
Hospitalization costa Daily cost of intensive therapy
ward
1450 Euro/day Direct costs: 1100 EUR/day
Indirect costs: 350 EUR/day
Francesco Copello,
personal communication,
March 2016Daily cost of other hospital wards 450 Euro/day Direct costs: 350 EUR/day
Indirect costs: 100 EUR/day
Mean compensation for transfusion-associated disease
Anamnestic data of
WNND notified cases
Sex and profession, thirty-day
follow up status, local health unit
(LHU) of notification
Description NA Surveillance form for
infectious diseases (SMI)
database
Symptoms onset date, date of
notification
Variable Date
Age at symptoms onset date Variable Years
Compensation for
TAD
Compensation for TAD
according to the subject’s income
class
Variableb Euro/year
for 15
years
[20,21]
NA: not applicable; TAD: transfusion-associated disease
a including direct costs (medical personnel, materials, health service) and indirect costs (hospital structure, direction, offices, light, phone, gas and cleaning).
b €10,000/year for 15 years for a subject retired or belonging to the lowest income class.
https://doi.org/10.1371/journal.pone.0188156.t002
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Public Health Service from surveillance activity, and were treated and analysed anonymously.
The details for the estimation of benefits are described below.
Short term cost of hospitalization. During the study period in Emilia-Romagna, each
confirmed WNND case was notified in the surveillance form for infectious diseases (SMI)
database and was identified by an anonymous id-code. This code allowed to link the hospital
discharge form (HDF) with the human surveillance information. For all WNND cases, data on
sex and profession, notification date, symptoms onset date, age at symptoms onset date, thirty-
day follow up status, and history of blood transfusion or organ transplant in the 28 days before
the symptoms onset date were obtained from the SMI database. All WNND cases hospitaliza-
tion data (date of admission and discharge to and from each hospital ward, ward type, primary
and secondary diagnosis) were obtained from the HDF database. Hospitalization records pre-
ceding the symptoms onset date were excluded from the analysis. Only the first hospitalization
occurring after the symptoms onset date was considered, and the possible consecutive hospi-
talization records resulting from the change of the hospital ward. All primary and secondary
diagnoses were checked to confirm that WNND was the cause of hospital admission. The hos-
pitalization length of stay of each WNND case was calculated as the sum of the duration of the
selected hospitalization events.
Short term cost of hospitalization was estimated for each WNND case considering the hos-
pitalization length of stay in each different hospital ward (days) times its relative daily cost.
Daily cost included direct costs (medical personnel, materials, health service) and indirect
costs (hospital structure, direction, offices, light, phone, gas, and cleaning). These costs were
indexed as information was collected and analysed in a public hospital of Genova for the year
2015 (Francesco Copello, personal communication, March 2016). This hospital was compara-
ble, in organization and structure, to the hospitals of Emilia-Romagna region in which all
patients were hospitalized. Eventually, based on a total of 76 hospitalization records of 52 out
of 53 confirmed WNND cases notified in Emilia-Romagna in the study period, a mean short
term cost of hospitalization of a WNND case was calculated.
Compensation for transfusion-associated disease. The value of the compensation for
transfusion-associated disease was obtained from the Italian regulation [20,21]. According to
the average age and occupation at the symptoms onset date of all confirmed WNND notified
cases in Emilia-Romagna in the study period, the mean compensation for transfusion-associ-
ated disease for the appropriate income class was considered.
Results
The estimates of the annual costs associated with WNV surveillance in Emilia-Romagna in
the study period for the One Health and for the uni-sectoral scenarios are reported in Tables
4 and 5, respectively. Entomological and ornithological surveillance represent the greater
annual surveillance cost. When implemented, blood screening and vector control represent
the most expensive public health interventions of this disease mitigation system. The costs of
Table 3. Duration (days) of hospitalization of 52 West Nile virus neuroinvasive disease cases occurred in Emilia-Romagna, 2009–2015.
Type of hospital ward No. of WNND cases Mean duration of hospitalization (days) Range (days)
Intensive care 4 32.8 7–73
Infectious and tropical diseases 29 13.2 2–55
Other hospital wards 33 29.5 1–184
Total 52 28.6 3–215
WNND: West Nile virus neuroinvasive disease
https://doi.org/10.1371/journal.pone.0188156.t003
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communication campaigns and vector control interventions are the same in both scenarios, as
they are related to the incidence of human cases that occurred in 2009, and in 2013–2015.
Cumulative nominal costs of surveillance activities and triggered interventions in the 2009–
2015 period are depicted in Table 6. The overall costs of the One Health and of the uni-sectoral
scenario were between €4.91 and 5.08 million, respectively. Blood donation testing was the
main cost component in in both scenarios, and was estimated to be €4.49 million in the uni-
Table 5. Cost evaluation for the uni-sectoral scenario–national plan for West Nile virus (WNV) surveil-
lance, Emilia-Romagna, Italy, 2009–2015.
Year Cost of
surveillance
activities
Cost of triggered public health interventions Overall
surveillance
cost (Euro)
Human
surveillance
Communication
campaigns
Vector
control
Blood screening
Cost of
diagnosis of
suspect
WNND cases
(Euro)
Communication
cost (Euro)
Vector
control
intervention
cost (Euro)
No. of
blood
units
tested
No. of
positive
blood
units
detected
Blood
screening
cost
(Euro)
2009a 5772 15,000 102,870 35,552 0 426,624 550,266
2010a 8362 15,000 0 66,689 0 800,268 823,630
2011a 4884 15,000 0 60,258 0 723,096 742,980
2012a 5476 15,000 0 0 0 0 20,476
2013b 14,726 15,000 102,870 53,898 8 610,125 742,721
2014b 16,798 15,000 102,870 79,554 0c 900,551 1,035,219
2015b 15,170 15,000 102,870 90,775 6 1,027,573 1,160,613
Total 71,188 105,000 411,480 386,726 14 4,488,238 5,075,906
WNND: West Nile virus neuroinvasive disease
Costs of blood screening activities for the years 2009–2013 are from Table 4 of Bellini et al. [3].
Blood screening activities
According to the national guidelines, mandatory screening of blood units is performed in a given year
between 1 July and 30 November in all blood donations of provinces (NUTS 3) where a human case of
WNND has been confirmed in the previous year. For other provinces that year, blood unit screening is only
initiated a week after a human WNND case is detected in the current season [3]. Moreover, nationwide, from
1 July to 30 November, blood donors having been for at least one night in the affected provinces shall be
deferred for 28 days, alternatively, they can be admitted to donate provided their donations are tested by
WNV NAT.
a The national regulation on blood safety is implemented in Emilia-Romagna during the year in question.
Only the results of human surveillance trigger public health interventions to mitigate the risk of WNV
transmission via blood transfusion (uni-sectoral scenario).
b From 2013, in ER, surveillance information generated in the animal health sector is integrated to guide
public health interventions to mitigate the risk of WNV transmission via blood transfusion (One Health
scenario), differing from the national guidelines (uni-sectoral scenario). Costs that would have been
generated by following the national guidelines have been estimated for the region, based on the knowledge
of the notification of human WNND cases in the previous year, and the knowledge of the time of occurrence
of human WNND cases at the province (NUTS3) level.
c In 2014 the National Blood Centre established that in Emilia-Romagna region, having an integrated
surveillance system in place, blood donation testing is implemented in a province from July 1, if WNV
circulation has been detected in any species in the same province in the previous two years. According to
this, one infected blood donation would have been detected in the province of Ravenna (2014) following the
national regulation. However, we considered 0 donations detected according to the uni-sectoral national
regulation implemented until 2013.
https://doi.org/10.1371/journal.pone.0188156.t005
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sectoral scenario, and €3.28 million in the One Health scenario. The One Health blood dona-
tion strategy resulted in €1.21 million savings in terms of avoided tests.
A mean short term cost of hospitalization of €15,396 per WNND case was calculated, refer-
ring to a mean hospitalization length of 28.6 days. Compensation for transfusion-associated
disease for a low income or retired subject, which was the case of 46/53 WNND cases (mean
age at symptoms onset: 70.0 years), was estimated to be €150,000 in fifteen years per subject.
In the study period, benefits due to avoided potential cases of WNND associated to infected
blood component transfusion in the One Health scenario were estimated to be €0, €330,792,
and €2.98 million in the best-case, intermediate, and worst-case scenario, respectively (Tables
7 and 8). These estimated benefits were due, in this analysis, to the detection of six infected
blood donations (18 potential WNV infected transfusion and zero, two, or 18 associated
WNND cases) that would have been undetected with the uni-sectoral approach.
Discussion
Our estimates suggest that the One Health approach to WNV surveillance is cost saving. A
total of €160,921 cost reduction can be achieved with the One Health scenario when compared
Table 6. Overall costs of the One Health and uni-sectoral scenarios, Emilia-Romagna, Italy, 2009–
2015.
One Health scenario cost (Euro) Uni-sectoral scenario cost (Euro)
Surveillance activities
Human surveillance 71,188 71,188
Entomological surveillance 646,505 0
Wild birds surveillance 245,320 0
Horse surveillance 2340 0
Sharing of information 156,800 0
Triggered interventions
Blood testing 3,276,352 4,488,238
Communication campaigns 105,000 105,000
Vector control interventions 411,480 411,480
4,914,985 5,075,906
https://doi.org/10.1371/journal.pone.0188156.t006
Table 7. Benefits of the One Health scenario: Parameters included in the calculation of the averted
costs of potential human cases of West Nile virus neuroinvasive disease (WNND) associated to
infected blood component transfusion, Emilia-Romagna, Italy, 2009–2015.
Parameter description Value Unit
Number of infected blood units intercepted in the One Health scenario only 6 Number
Number of assumed WNND cases avoided in the One Health scenario only Table 8 Number
Number of confirmed WNND cases notified in Emilia-Romagna in 2009–2015 53 Number
Number of confirmed WNND cases in Emilia-Romagna in the study period with
hospitalization records
52 Number
Number of hospitalization records considered in the estimation 76 Number
Mean hospitalization length of a WNND case 28.6 Days
Mean short term cost of hospitalization of a WNND case 15,396 Euro
Mean compensation for transfusion-associated disease per subject 150,000a Euro
WNND: West Nile virus neuroinvasive disease
a Compensation in fifteen years.
https://doi.org/10.1371/journal.pone.0188156.t007
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to the uni-sectoral scenario considered in this work. Benefits of the One Health approach due
to avoided short term costs of hospitalization and avoided compensation for transfusion-asso-
ciated disease of potential WNND human cases were estimated to be €0, €330,792, and €2.98
million in the best-case, intermediate, and worst-case scenario, respectively.
Enhanced cooperation of human and animal health sector is considered to be crucial in
order to improve the management of zoonoses, including WNV. Such cooperation enables
the adoption of targeted measures and is expected to be more efficient and resource-saving,
compared to a non integrated approach [22]. In a context of increasing pressure on public
and private resources allocated to surveillance and intervention activities aimed at reducing
the impact of zoonoses in society [9], it is worthwhile considering the economic implications
of different public health strategies. In this work, the One Health approach was more efficient
from an economic standpoint than the uni-sectoral approach. In fact, although the integrated
WNV surveillance was resource intensive, the savings associated with the One Health ap-
proach compensated the costs of this surveillance system. These savings were due to a more
targeted, evidence-based testing strategy, triggered by real-time area-specific WNV detection
by the integrated surveillance system. Moreover, the One Health approach provided an early
and timely warning of WNV presence in the animal and vector populations at the province
level. This enabled the interception of infected asymptomatic blood donors (otherwise unde-
tected) in the same space frame, resulting in substantial benefits associated to averted potential
WNND cases due to infected blood component transfusion.
To our knowledge, studies of the comparative economic efficiency of One Health ap-
proaches compared to uni-sectoral approaches to vector-borne zoonoses management remain
scarce and largely absent from the published literature. Previous work conducted to estimate
the economic aspects of vector-borne zoonoses surveillance, prevention and control, have
focused so far on uni-sectoral approaches, and conducted mainly in the United States (US).
Few studies on the economic burden of WNV infection, including financial consequences of
WNND and vector control interventions, have been carried out in Europe. In our study, a
mean short-term cost of hospitalization of €15,396 per WNND case was estimated, with a
mean hospital stay of 28.6 days. Humblet et al. [23] estimated the impact of a potential epi-
demic in Belgium, finding a cost of €3553 for a WNND case, and the €4441 for an acute flaccid
Table 8. Benefits of the One Health scenario quantified as averted costs of potential human cases of
West Nile virus neuroinvasive disease (WNND) associated to infected blood component transfusion.
Best-case, intermediate, and worst-case scenario according to the probability of WNND transfusion associ-
ated transmission. Emilia-Romagna, Italy, 2009–2015.
Best-case
scenario
Intermediate
scenario
Worst-case
scenario
Short term cost of hospitalization avoided
(Euro)
0 30,792 277,128
Compensation for transfusion-associated
disease avoided (Euro)
0 300,000 2,700,000
Total benefit of the One Health scenario
(Euro)
0 330,792 2,977,128
WNND: West Nile virus neuroinvasive disease
Benefits of the One Health scenario are estimated as potential transfusion associated West Nile virus
neuroinvasive disease (WNND) cases avoided. Three scenarios are considered based on the assumed
probability of developing WNND after receiving an infected blood transfusion. This probability was assumed
to be 0%, 10%, and 100% in the best-case, intermediate, and worst-case scenario, resulting in 0, 2, and 18
potential WNND cases avoided, respectively.
https://doi.org/10.1371/journal.pone.0188156.t008
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paralysis case, considering a mean hospitalization length of nine days. Adjusting for hospitali-
zation length, our results are similar to those obtained in that study. Kolimenakis et al. [24]
performed a cost-benefit analysis of the public control strategies to tackle the 2010 WNV out-
break in the Region of Central Macedonia, Greece. The authors estimated an average cost of
illness of about €4000 per hospitalised patient, including hospitalization costs and productivity
losses. This estimation was lower compared to our findings, and was based on lower daily hos-
pital care cost in Greek hospitals. Our estimates are in line with the US study of Staples et al.
[25], that quantified a median cost (i.e. initial hospital and lost productivity costs) of US
$20,774 (approximately €18,715, considering the European Central Bank yearly average
exchange rate in 2015 of €1.11 to US$1 [26]) for a patient with neurologic disease. The major-
ity of this cost was incurred as a result of hospital charges. Barber et al. [27] estimated a cost of
US$33,143 (€28,094, value updated to the European Central Bank yearly average exchange
rate in 2015 would be €29,859) including inpatient treatment costs but not including outpa-
tient care, lost productivity, and miscellaneous expenses. A US$27,500 (€24,775) cost per case
of neuroinvasive WNV illness with full recovery was estimated in the works on the 2002 WNV
epidemic in Louisiana [28,29].
Concerning vector control intervention, a mean annual cost of ground adult mosquito con-
trol interventions of €102,870 was obtained. Our estimate is lower to the annual cost of about
€4 million to tackle the 2010 WNV outbreak in Greece [24]. Similar studies would be needed
to add this sort of information to the body of knowledge, as these are important aspects for
post epidemic strategy decision making. Several works have been carried out in the USA. [27]
estimated a total cost of US$701,790 (€632,243) for the mosquito control aerial spray after an
human outbreak in the Sacramento County, California in 2005. The cost of mosquito control
of the 2002 WNV epidemic in Louisiana was estimated to be US$8.3 million (€7.5 million)
[29]. To our knowledge, these costs are not comparable, and aerial spray would unlikely be
implemented in the European context, because of its heavy environmental impact [30].
There are several limitations to our estimations and areas where overestimation or underes-
timation of costs and benefits are possible, mainly due to a lack of data. For the hospitalized
WNND cases, only a 30-day follow up after hospital discharge was available. Thus, long term
cost of illness (e.g. home care, rehabilitation, durable medical equipment, medication, medical
appointments) was not calculated at this stage. Furthermore, costs associated with the death of
patients (compensation paid to the family, additional possible compensation requests within
instances of transfusion associated diseases, private insurance claims) were not considered for
a lack of data. Indirect impact of WNND (e.g. work absenteeism) was not quantified. However,
it was assumed that this cost would not have a big impact on our benefit estimation, consider-
ing the mean age at symptoms onset of our cases (70.0 years). Costs were valued in nominal
prices. There has been no attempt to adjust for inflation over the period because in both sce-
narios inflation rates would have been similar or the same, and the levels of inflation during
the period were low. Averted compensation for potential transfusion-associated disease was
the major benefit of the One Health scenario. Further benefits resulting from the averted costs
related to legal actions after transfusion-associated disease were not quantified and included
for a lack of data. Supplemental intangible costs attributable to the loss of reputation of the
regional public health service, due to the occurrence of a human case after an infected transfu-
sion, were not quantified at this stage. Similarly, any benefit streams associated with the
reduced impact of disease in the horse population were not quantified.
Additional limitations are linked to the assumption that a WNV positive blood component
donation always resulted in infection, as in the work of Korves et al. [31], and to the assump-
tion of the probability of developing WNND after infected transfusion. A higher risk of disease
in patients who were infected via blood transfusion based on their age and immune system
Cost and benefits integrated WNV surveillance
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status was not taken into account for a lack of these data. To the best of our knowledge, there is a
lack of literature on the probability of disease transmissibility via blood transfusion. Thus, to
address the possibility of different probabilities of TAD, three scenarios were considered using
0%, 10%, and 100% probability values. However, even considering a 0% probability of developing
WNND in patients receiving a WNV positive blood component donation, the One Health sce-
nario would still be economically beneficial, due to savings in surveillance activities (Table 6).
The estimation of blood screening cost might be an underestimation, as donor notification,
retrieval of a test-positive sample, and personnel costs were not included as in the work of
Korves et al. [31]. A cost for a single NAT-test on a blood-donor’s sample ranging from €11.32
(2013–2015), to €12.00 (2009–2011), and €12.10 (2012) was found. This estimation would be
less than the €18 for single WNV-NAT test, including personnel and other overhead costs,
estimated by Niederhauser et al. [32].
Human surveillance costs might have been underestimated as personnel cost was not
included in the quantification of the mean cost of diagnosis of a human neurologic case (€74),
due to a lack of data. The costs related to veterinary inspection and outbreak investigations
after the confirmation of an equine WNV neurologic disease case was not quantified, because
these activities did not have additional consequences on public health interventions. For the
same reason, costs incurred by the horse owner (e.g. sample transportation to the laboratory,
voluntary vaccination) were not included in this study.
Allocation of costs to specific WNV-related activities was not always possible. This resulted
in a possible underestimation of information sharing cost. In fact, the time used to share sur-
veillance data via email, telephone, and the epidemiologic bulletin could not be quantified.
Communication campaigns cost might have been overestimated because communication
materials were designed to inform the general population on the prevention of vector borne
diseases (e.g. dengue, chikungunya, zika, leishmaniasis, etc.) in which WNND is included.
Although human infection is most often the result of bites from WNV infected mosquitoes,
it is of utmost importance for public health decision makers to ensure the absence of viral
transmission through hospital practices (i.e. blood transfusion and organ transplant) in order
to maintain the trust in the public health system. During the 2009–2015 period, no WNND
cases associated to a WNV infected blood transfusion were recorded in Emilia-Romagna. In
fact, none of the hospitalized WNND received blood transfusions or organ transplants in the
28 days before symptoms onset. Breast feeding and laboratory related exposure were excluded
considering the age and profession of all WNND cases. These data support the efficacy of the
blood safety policy adopted in Emilia-Romagna region.
Better quality data, namely on long term costs of human disease, communication cam-
paigns and vector control activities and voluntary horse vaccination is needed to more accu-
rately assess the economic impact of WNV infection. Further economic assessments including
long term costs of human disease, and the evaluation of intangible costs and sociological and
ecological dimensions would allow a more complete understanding of the impact of the dis-
ease as well as of the economic efficiency of different disease mitigation strategies.
Blood screening was the main cost associated to WNV surveillance in this endemic region.
It is therefore essential to invest in quantitative and qualitative research on the evaluation of
different blood safety strategies and their economic impact. The One Health blood safety strat-
egy is cost saving in our case. Moreover, it can enable an early warning of WNV presence in
the environment, and the prevention of potential human infections via infected blood transfu-
sion, resulting in substantial benefits.
Our results provide important evidence on the economic return of One Health surveillance
for vector-borne zoonoses in Europe, and can further the evidence for the prioritization of
resources allocated to zoonoses surveillance and prevention within a One Health context.
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Conclusion
Emilia-Romagna is a WNV endemic area. In this epidemiological context, the implementation
of a permanent WNV surveillance system seems necessary. An integrated surveillance system,
as the one implemented in the region, can lead to accelerated WNV detection and the preven-
tion of human infections. Moreover, it allows the collection of data that are useful to better
understand the epidemiology of WNV infection, and to identify possible risk factors related to
human infections.
Joint WNV surveillance efforts of the public and the animal health sectors are resource inten-
sive activities. However, our results can bring evidence on the economic return of such coopera-
tion for zoonoses mitigation in Europe. These results can contribute to build an evidence base for
One Health operations, with the aim to guide disease mitigation policy, decision making, and
capacity building within a One Health context. Further evaluations including intangible costs,
social, and ecological dimensions, would allow a deeper understanding of the economic context
of the disease and its mitigation, allowing to better inform public health decision makers.
Supporting information
S1 Table. West Nile neuroivasive disease cases hospitalization dataset.
(XLSX)
Acknowledgments
The authors would like to thank Adriana Giannini, Claudio Gualanduzzi, Claudio Velati,
Claudio Venturelli, Diana Venturini, Mattia Calzolari, Michele Dottori, Nadia Pascarelli and
Paolo Bonilauri for their collaboration. The authors would also like to acknowledge all the per-
sonnel supporting the activities of the integrated surveillance system.
Author Contributions
Conceptualization: Giulia Paternoster, Sara Babo Martins.
Data curation: Giulia Paternoster.
Formal analysis: Giulia Paternoster, Andrea Mattivi.
Investigation: Giulia Paternoster, Andrea Mattivi, Francesco Copello.
Methodology: Giulia Paternoster, Sara Babo Martins.
Resources: Andrea Mattivi, Roberto Cagarelli, Paola Angelini, Romeo Bellini, Simonetta
Pupella, Francesco Copello, Marco Tamba.
Supervision: Jonathan Rushton, Katharina D. C. Sta¨rk, Marco Tamba.
Writing – original draft: Giulia Paternoster.
Writing – review & editing: Giulia Paternoster, Sara Babo Martins, Andrea Mattivi, Roberto
Cagarelli, Paola Angelini, Romeo Bellini, Annalisa Santi, Giorgio Galletti, Simonetta
Pupella, Giuseppe Marano, Francesco Copello, Jonathan Rushton, Katharina D. C. Sta¨rk,
Marco Tamba.
References
1. Macini P, Squintani G, Finarelli AC, Angelini P, Martini E, Tamba M, et al. Detection of West Nile virus
infection in horses, Italy, September 2008. Euro Surveill. 2008; 13(41):pii = 19002. Available online:
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19002
Cost and benefits integrated WNV surveillance
PLOS ONE | https://doi.org/10.1371/journal.pone.0188156 November 27, 2017 14 / 16
2. Rossini G, Cavrini F, Pierro A, Macini P, Finarelli A, Po C, et al. First human case of West Nile virus neu-
roinvasive infection in Italy, September 2008—case report. Euro Surveill. 2008; 13(41):pii = 19002.
Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19002
3. Bellini R, Calzolari M, Mattivi A, Tamba M, Angelini P, Bonilauri P, et al. The experience of West Nile
virus integrated surveillance system in the Emilia-Romagna region: five years of implementation, Italy,
2009 to 2013. Euro Surveill. 2014; 19(44): pii = 20953. Available online: http://www.eurosurveillance.
org/ViewArticle.aspx?ArticleId=20953
4. Emilia-Romagna Region. Piano di sorveglianza e controllo malattia West Nile, Chickungunya e Dengue e
altri arbovirus in Emilia-Romagna, anno 2013. [Regional surveillance plan for West Nile Disease, Chickun-
gunya, Dengue and other arboviruses in Emilia-Romagna, year 2013]. 2013. Available online: http://salute.
regione.emilia-romagna.it/documentazione/piani-e-programmi/piano_arbovirosi_rer_2013.pdf
5. Emilia-Romagna Region. Piano sorveglianza arbovirosi 2014 [Regional arboviruses surveillance plan
2014]. 2014. Available online: http://www.izsler.it/izs_bs/allegati/736/PIANO SORVEGLIANZA
ARBOVIROSI 2014.pdf
6. Emilia-Romagna Region. Piano sorveglianza arbovirosi 2015 [Regional arboviruses surveillance plan
2015]. 2015. Available online: http://www.zanzaratigreonline.it/Portals/zanzaratigreonline/
PianoregionaleSorveglianzaArbovirosi2015.pdf
7. European Commission. Commission Directive 2014/110/EU of 17 December 2014 amending Directive
2004/33/EC as regards temporary deferral criteria for donors of allogeneic blood donations. Official
Journal of the European Union. Luxembourg: Publications Office of the European Union. 20.12.2014 L
366. 2014.
8. Tisdell C. Economics of Controlling Livestock Diseases: Basic Theory. In: Rushton J, editor. Economics
of Animal Health & Production. Wallingford, UK: CABI; 2009. p. 46–9.
9. Babo Martins S, Rushton J, Sta¨rk KDC. Economic Assessment of Zoonoses Surveillance in a “One
Health” Context: A Conceptual Framework. Zoonoses Public Health. 2016; 63(5):386–95. https://doi.
org/10.1111/zph.12239 PMID: 26607752
10. Napoli C, Iannetti S, Rizzo C, Bella A, Di Sabatino D, Bruno R, et al. Vector borne infections in Italy:
results of the integrated surveillance system for West Nile disease in 2013. Biomed Res Int. 2015;
2015:643439. Available online: https://www.hindawi.com/journals/bmri/2015/643439/ https://doi.org/
10.1155/2015/643439 PMID: 25874224
11. Pisani G, Cristiano K, Pupella S, Liumbruno GM. West Nile Virus in Europe and Safety of Blood Trans-
fusion. Transfus Med Hemotherapy. 2016; 43(3):158–67. Available online: http://www.ncbi.nlm.nih.gov/
pubmed/27403087
12. Angelini P, Tamba M, Finarelli AC, Bellini R, Albieri A, Bonilauri P, et al. West Nile virus circulation in
Emilia-Romagna, Italy: the integrated surveillance system 2009. Euro Surveill. 2010; 15(16):19547.
PMID: 20430000.
13. Calzolari M, Gaibani P, Bellini R, Defilippo F, Pierro A, Albieri A, et al. Mosquito, bird and human surveil-
lance of West Nile and Usutu viruses in Emilia-Romagna Region (Italy) in 2010. PLoS ONE. 2012; 7(5):
e38058. Available online: https://doi.org/10.1371/journal.pone.0038058 PMID: 22666446
14. Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia-Romagna (IZSLER). Tariffario presta-
zioni di laboratorio [Laboratory price list]. Available online: http://www.izsler.it/izs_bs/ftp/materiali_ftp/
tariffarioIZSLER.pdf
15. Emilia-Romagna Region. Progetto per la realizzazione di un sistema integrato di sorveglianza sanitaria
delle malattie trasmesse da artropodi vettori in Emilia-Romagna. Assegnazione e concessione finanzia-
mento all’azienda USL della Romagna. [Regional project for the integrated surveillance of vector-borne
diseases in Emilia-Romagna. Assignment of funding to the Romagna Local Health Unit]. GPG/2015/
494. Bologna; 2015.
16. Emilia-Romagna Region. Progetto per la realizzazione di un sistema integrato di sorveglianza sanitaria
delle malattie trasmesse da artropodi vettori in Emilia-Romagna. Assegnazione e concessione finanzia-
mento all’azienda USL della Romagna. [Regional project for the integrated surveillance of vector-borne
diseases in Emilia-Romagna. Assignment of funding to the Romagna Local Health Unit]. GPG/2014/
396. Bologna; 2014.
17. Canali M, Rivas S. Controllo della Zanzara-Tigre: analisi dei costi sostenuti dagli Enti Locali. Emilia-
Romagna Report 2008–2011 [Emilia-Romagna report on the costs allocated for tiger mosquito control
activities by the Local Health Units, 2008–2011]. Bologna; 2012; 45–46.
18. Ministero della Salute. [Italian Ministry of Health]. West Nile Disease. Procedure operative di intervento
e flussi informativi nell’ambito del Piano di sorveglianza nazionale per la Encefalomielite di tipo West
Nile (West Nile Disease), anno 2014 [West Nile Disease: procedures and information flow within the
National surveillance plan for equine West Nile virus neurologic disease, year 2014]. 2014; Available
online: http://www.gazzettaufficiale.it/eli/id/2014/07/18/14A05608/sg
Cost and benefits integrated WNV surveillance
PLOS ONE | https://doi.org/10.1371/journal.pone.0188156 November 27, 2017 15 / 16
19. World Health Organization (WHO). West Nile virus Fact sheet No. 354. 2011. Available online: http://
www.who.int/mediacentre/factsheets/fs354/en/ last access 06/09/2017
20. Ministero della Salute. [Italian Ministry of Health]. Indennizzo a favore dei soggetti danneggiati da com-
plicanze di tipo irreversibile a causa di vaccinazioni obbligatorie, trasfusioni [Compensation for individu-
als harmed by irreversible complications resulting from compulsory vaccinations, transfusions and the
administration of blood derivatives]. National law 210/1992; Available online http://www.salute.gov.it/
imgs/C_17_normativa_1556_allegato.pdf
21. Ministero della Salute. [Italian Ministry of Health]. Tabella importi indennizzo rivalutati fino all’anno 2017
[Tables of the amount of the compensation according to the National law 210/1992, values updated
until the year 2017]. Available online: http://www.indennizzolegge210.it/detail.asp?c=13&p=0&id=905
22. Gossner CM, Marrama L, Carson M, Allerberger F, Calistri P, Dilaveris D, et al. West nile virus surveil-
lance in Europe: Moving towards an integrated animal-human-vector approach. Euro Surveill. 2017; 22
(18):pii = 30526. https://doi.org/http://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.
22.18.30526
23. Humblet M, Vandeputte S, Fecher-Bourgeois F, Le´onard P, Gosset C, Balenghien T, et al. Estimating
the economic impact of a possible equine and human epidemic of West Nile virus infection in Belgium.
Euro Surveill. 2016; 21(31):pii = 30309. https://doi.org/https://doi.org/10.2807/1560-7917.ES.2016.21.
31.30309
24. Kolimenakis A, Bithas K, Richardson C, Latinopoulos D, Baka A, Vakali A, et al. Economic appraisal of
the public control and prevention strategy against the 2010 West Nile Virus outbreak in Central Macedo-
nia, Greece. Public Health. 2016; 131:63–70. Available online: http://dx.doi.org/10.1016/j.puhe.2015.
10.023
25. Staples JE, Shankar MB, Sejvar JJ, Meltzer MI, Fischer M. Initial and long-term costs of patients hospi-
talized with West Nile virus disease. Am J Trop Med Hyg. 2014; 90(3):402–9. Available online: http://
www.ajtmh.org/content/90/3/402.long https://doi.org/10.4269/ajtmh.13-0206 PMID: 24515937
26. European central bank, Euro foreign exchange reference rates https://www.ecb.europa.eu/stats/
policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html, last access 08/03/
2017
27. Barber LM, Schleier JJ, Peterson RKD. Economic Cost Analysis of West Nile Virus Outbreak, Sacra-
mento County, California, USA, 2005. Emerg Infect Dis. 2010; 16(3):480–6. Available online: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3322011&tool=pmcentrez&rendertype=abstract
https://doi.org/10.3201/eid1603.090667 PMID: 20202424
28. Zohrabian A, Hayes EB, Petersen LR. Cost-effectiveness of West Nile virus vaccination. Emerg Infect
Dis. 2006; 12(3):375–80. Available online: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
3291438&tool=pmcentrez&rendertype=abstract https://doi.org/10.3201/eid1203.050782 PMID:
16704772
29. Zohrabian A, Meltzer MI, Ratard R, Billah K, Molinari NA, Roy K, et al. West Nile virus economic impact,
Louisiana, 2002. Emerg Infect Dis. 2004; 10(10):1736–44. Available online: https://www.ncbi.nlm.nih.
gov/pmc/articles/PMC3323281/ https://doi.org/10.3201/eid1010.030925 PMID: 15504258
30. Bellini R, Zeller H, Van Bortel W. A review of the vector management methods to prevent and control
outbreaks of West Nile virus infection and the challenge for Europe. Parasit Vectors. 2014; 7:323. Avail-
able online: http://www.parasitesandvectors.com/content/7/1/323 https://doi.org/10.1186/1756-3305-7-
323 PMID: 25015004
31. Korves CT, Goldie SJ, Murray MB. Cost-effectiveness of alternative blood-screening strategies for
West Nile virus in the United States. PLoS Med. 2006; 3(2):0211–21. Available online: http://journals.
plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030021
32. Niederhauser C, Fontana S, Glauser A, Steinemann C, Koller A. West Nile Virus preparedness plan to
ensure safe blood components in Switzerland: a risk-based approach. 2016;1–8. Available online:
http://onlinelibrary.wiley.com/doi/10.1111/voxs.12300/pdf
Cost and benefits integrated WNV surveillance
PLOS ONE | https://doi.org/10.1371/journal.pone.0188156 November 27, 2017 16 / 16
